Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EBP | Q15125 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.36 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6958291 | 0.82 | KDM4E (0.35) | EBPSIGMAR1KDM4EPOLBHTT | |
| SCHEMBL9975318 | 0.82 | EBP (0.43) | EBPSIGMAR1KDM4EPOLBHTT | |
| SCHEMBL14878207 | 0.77 | PSMB1 (0.34) | KDM4ETDP1LMNA | |
| SCHEMBL14878212 | 0.77 | GAA (0.37) | SIGMAR1KDM4EPOLBMEN1KMT2A | |
| SCHEMBL151956 | 0.69 | SIGMAR1 (0.59) | EBPSIGMAR1KDM4EPOLBHTT | |
| SCHEMBL13034078 | 0.67 | KDM4E (0.47) | EBPSIGMAR1KDM4EPOLBHTT | |
| SCHEMBL6366377 | 0.67 | SIGMAR1 (0.57) | EBPSIGMAR1KDM4EPOLBHTT | |
| SCHEMBL6367277 | 0.67 | SIGMAR1 (0.57) | EBPSIGMAR1KDM4EPOLBHTT | |
| SCHEMBL13083284 | 0.67 | EBP (0.52) | EBPSIGMAR1KDM4EPOLBHTT | |
| SCHEMBL14104119 | 0.67 | EBP (0.52) | EBPSIGMAR1KDM4EPOLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349857-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2013-01-08 | — | — | US | disclosed |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | ERBB2, EGFR, ABL1 | EBP 3224/4885SIGMAR1 98/4885KDM4E 2805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.